chevron_leftBack
L
As of 13 June 2026, Lunai Bioworks Inc. has a market cap of $12.07M USD, ranking #40249 globally and #5244 in the United States.
It ranks #3588 in the Healthcare sector, and #699 in the Biotechnology industry.
Key Stats
Market Cap
$12.07MUSD
Enterprise Value
$14.5MUSD
EBITDA (TTM)
-$12.46MUSD
Net Income (TTM)
-$125.52MUSD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
David Weinstein
open_in_new
Employees
29
Website
lunaibioworks.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.1% | 1.1% | -20% | -59% | -68% | -91% |
News
Loading...
RENB Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
RENB
ISIN: US29350E2037
Shares Out.:
Shares Outstanding:
23.178M1
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
0.3327 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Lunai Bioworks Inc.
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
2M%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
1M%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
229K%
|
-
|
|
NYSE: IQV
|
$26.3B
218K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
207K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
150K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
396K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
371K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
351K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
350K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
233K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
213K%
|
-
|
chevron_leftBack